Clinical value of magnetic resonance DKI technique in the nigrostriatal region of Parkinson's disease patients and its correlation with clinical progress
-
摘要:
目的探讨扩散峰度成像(DKI)技术在特发性帕金森患者黑质纹状体区的临床价值,分析其与临床进展的相关性。 方法选取我院经临床确诊为帕金森病的患者35例为观察组,收集同期我院就诊的健康对照人群20例为对照组,所有受试者均在3.0 T磁共振成像机上进行MRI常规扫描、DKI序列扫描,在后处理的DKI序列上分别测量双侧黑质(SN)区的平均弥散分度值、各向异性分数值、轴向峰度值、径向峰度值。比较两组平均弥散分度、各向异性分数、轴向峰度、径向峰度均值,寻找各脑区存在差异的影像学指标。将观察组患者分为帕金森早期组(n=13)及进展期组(n=22),寻找DKI中平均弥散分度、各向异性分数值与临床病程进展有无相关性。 结果观察组双侧黑质平均弥散分度均数值较对照组明显增高,差异具有统计学意义(P < 0.05);各向异性分数值较对照组减小,差异具有统计学意义(P < 0.05);轴向峰度、径向峰度值差异无统计学意义(P>0.05)。早期帕金森组和进展期帕金森组双侧黑质平均弥散分度及各向异性分数值与临床病程、分级均未发现显著相关性(P>0.05)。 结论DKI参数中平均弥散分度值及各向异性分数值可以成为神经退化过程的早期生物标志物。DKI中平均弥散分度、各向异性分数值暂不适用评估帕金森患者病情进展程度。 Abstract:ObjectiveTo explore the clinical value of Diffusion Kurtosis Imaging (DKI) in nigrostriatal region of idiopathic Parkinson's disease and analyze the correlation with clinical progress. MethodsThirty-five patients diagnosed of Parkinson's disease in Xinjiang Second Clinical Hospital were selected as the case group, and 20 healthy control patients in our hospital during the same period were collected as the control group. All subjects underwent MRI routine scanning and DKI sequence scanning on a 3.0 T magnetic resonance imaging machine. The mean Kurt Osis (MK) values of bilateral substantia nigra were measured on the postprocessed DKI sequence respectively. The average values of MK, Anisotropic fraction (FA), axial kurtosis (AK) and radial kurtosis (RK) in the brain of the case group and the control group between 2 groups were compared. Patients in the case group were divided into early Parkinson's disease group (n=13) and advanced Parkinson's disease group (n=22). ResultsThe mean values of MK in the bilateral substantia nigra of the case group were significantly higher than those of the control group (P < 0.05), while the FA values were lower than those of the control group (P < 0.05). The AK and RK values between 2 groups had no significant difference (P>0.05). No significant correlation was found between MK and FA values of bilateral substantia nigra in early PD group and advanced PD group (P>0.05). ConclusionMK and FA values in DKI parameters can be used as early biomarkers of neurodegeneration. MK and FA values in DKI are not suitable for evaluating the progress of PD patients. -
Key words:
- diffusion kurtosis imaging /
- Parkinson's disease /
- nigrostriatal
-
图 1 男,65岁,帕金森病患者,左侧上肢不自主抖动3年余
A: b值=0时所选的双侧黑质范围,双侧黑质体素均为188, 面积均约50 mm2, 黑色箭头所指代表黑质区(下同); B:黑质 MK图,经测量患者双侧黑质区MK值较正常对照组明显增高; C:黑质FA图, 经测量双侧黑质FA值较对照组减低; D:黑质RK图, 经测量双侧黑质RK值均较对照组无明显变化; E:黑质AK图, 经测量双侧黑质AK值均较对照组无明显变化
Figure 1. Male, 65 years old, with Parkinson disease, had been involuntary shaking of left upper limb for more than 3 years
表 1 两组患者双侧黑质各参数的比较(Mean±SD)
Table 1. Comparison of parameters of bilateral substantia nigra in patients with two groups
指标 对照组(n=20) 观察组(n=35) t P 右侧黑质 MK值 1.10±0.14 1.39±0.11 8.47 0.000 FA值 0.56±0.13 0.47±0.12 -2.55 0.014 AK值 0.92±0.12 0.92±0.14 -0.11 0.99 RK值 1.16±0.16 1.11±0.16 -1.18 0.24 左侧黑质 MK值 1.13±0.13 1.35±0.08 7.5 0.000 FA值 0.55±0.05 0.46±0.04 -6.5 0.000 AK值 0.95±0.15 0.95±0.13 -0.18 0.85 RK值 1.07±0.15 1.08±0.16 0.25 0.80 MK: Mean kurtosis; FA: Fractional anisotropy; AK: Axial kurtosis; RK: Radial kurtosis. 表 2 双侧黑质区MK、FA值与病程及临床量表的相关性
Table 2. Correlation analysis results of bilateral substantia nigra MK values with disease course and clinical scale
指标 病程 Hoehn-Yahr UPDRS r P r P r P MK值 右侧黑质 -0.03 0.89 0.04 0.82 -0.07 0.69 左侧黑质 -0.05 0.76 0.02 0.92 -0.09 0.61 FA值 右侧黑质 -0.36 0.03 -0.08 0.66 0.06 0.75 左侧黑质 -0.10 0.58 -0.05 0.76 0.14 0.43 UPDRS: Unified Parkinson's Disease Rating Scale. -
[1] Xiang M, Glasauer S, Seemungal BM. Quantitative postural models as biomarkers of balance in Parkinson's disease[J]. Brain, 2018, 141 (10): 2824-7. doi: 10.1093/brain/awy250 [2] Brettschneider J, Del Tredici K, Lee VM, et al. Spreading of pathology in neurodegenerative diseases: a focus on human studies [J]. Nat Rev Neurosci, 2015, 16(2): 109-20. doi: 10.1038/nrn3887 [3] Kamagata K, Tomiyama H, Hatano T, et al. A preliminary diffusional kurtosis imaging study of Parkinson disease: comparison with conventional diffusion tensor imaging[J]. Neuroradiology, 2014, 56 (3): 251-8. [4] Zhang GH, Zhang YH, Zhang CG, et al. Striatal silent lacunar infarction is associated with changes to the substantia nigra in patients with early-stage Parkinson's disease: a diffusion kurtosis imaging study[J]. J Clin Neurosci, 2016, 33(11): 138-41. [5] Schwarz S, Bajaj N, Gowland PA, et al. MR imaging of the substantia nigra for the diagnosis of Parkinson disease[J]. Radiology, 2014, 273 (2): 627-8. doi: 10.1148/radiol.14141040 [6] Tan Y, Zhang H, Wang X, et al. Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas[J]. Clin Radiol, 2019, 74(4): 314-20. doi: 10.1016/j.crad.2018.12.004 [7] 王玉亮, 初建平.磁共振扩散峰度成像(DKI)临床研究进展[J].影像诊断与介入放射学, 2015, 24(4): 340-5. doi: 10.3969/j.issn.1005-8001.2015.04.017 [8] Cheng JX, Zhang HY, Peng ZK, et al. Divergent topological networks in Alzheimer's disease: a diffusion kurtosis imaging analysis[J]. Transl Neurodegener, 2018, 7: 10-8. doi: 10.1186/s40035-018-0115-y [9] 张家慧, 郎宁, 袁慧书.磁共振扩散峰度成像的临床研究进展[J].磁共振成像, 2018, 9(4): 316-20. http://d.old.wanfangdata.com.cn/Periodical/yxzdyjrfsx201504017 [10] Hall S, Surova Y, Ohrfelt A, et al. CSF biomarkers and clinical progression of Parkinson disease[J]. Neurology, 2015, 84(1): 57-9 doi: 10.1212/WNL.0000000000001098 [11] Foulds P, Mann DM, Mitchell JD, et al. Parkinson disease: Progress towards a molecular biomarker for Parkinson disease[J]. Nat Rev Neurol, 2010, 6(7): 359-61. doi: 10.1038/nrneurol.2010.78 [12] Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype[J]. Mov Disord, 2015, 30 (3): 350-8. [13] Prakash KG, Bannur BM, Chavan MD, et al. Neuroanatomical changes in Parkinson's disease in relation to cognition: an update[J]. JAdv Pharm Technol Res, 2016, 7(4): 123-6. doi: 10.4103/2231-4040.191416 [14] Zhang GH, Zhang YH, Zhang CG, et al. Diffusion kurtosis imaging of substantia nigra is a sensitive method for early diagnosis and disease evaluation in Parkinson's disease[J]. Parkinsons Dis, 2015, 15: 207624-32. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=Doaj000004064738 [15] Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists[J]. J Neurochem, 2016, 139(Suppl 1): 325-37. [16] Struyfs H, van Hecke W, Veraart J, et al. Diffusion kurtosis imaging: a possible MRI biomarker for AD diagnosis[J]. J Alzheimers Dis, 2015, 48(4): 937-48. doi: 10.3233/JAD-150253 [17] Shi M, Liu CQ, Cook TJ, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease[J]. Acta Neuropathol, 2014, 128(5): 639-50. doi: 10.1007/s00401-014-1314-y [18] Kosta P, Argyropoulou MI, Markoula S, et al. MRI evaluation of the basal Ganglia size and iron content in patients with Parkinson's disease[J]. J Neurol, 2006, 253(1): 26-32. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=d85328fd0bbc90cd867bb4792e70695a [19] 司海娜, 田玉玲, 王效春, 等.不同运动亚型帕金森病患者脑深部核团扩散峰度成像的比较研究[J].中华神经科杂志, 2019, 52(5): 379-86. doi: 10.3760/cma.j.issn.1006-7876.2019.05.004 [20] 孙亚琼, 张沁, 蒋震, 等.帕金森病患者脑深部核团的磁共振扩散峰度成像分析及临床意义[J].中华医学杂志, 2017, 97(45): 3534-7. doi: 10.3760/cma.j.issn.0376-2491.2017.45.004 [21] Focke NK, Helms G, Pantel PM, et al. Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging[J]. Am J Neuroradiol, 2011, 32(11): 2087-92. doi: 10.3174/ajnr.A2865 [22] Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease[J]. Nat Rev Neurosci, 2017, 18(7): 435-50. doi: 10.1038/nrn.2017.62 [23] Ito K, Sasaki M, Ohtsuka C, et al. Differentiation among parkinsonisms using quantitative diffusion kurtosis imaging[J]. Neuroreport, 2015, 26(5): 267-72. doi: 10.1097/WNR.0000000000000341 [24] Jiang H, Song N, Jiao Q, et al. Iron pathophysiology in parkinson diseases[J].Adv Exp Med Biol, 2019, 1173: 45-66.